Medicare’s own consumer website carries a specific caution about TrumpRx.gov and similar prescription discount cards: using one to buy a drug, in place of a Medicare plan, does not move a beneficiary any closer to that plan’s deductible or annual out-of-pocket maximum. The Centers for Medicare & Medicaid Services keeps this guidance posted on its “Help with drug costs” page, confirmed live as of September 9, 2026, alongside instructions for treating TrumpRx as a price-comparison tool rather than a pharmacy. The distinction sets up a real financial tension for anyone managing an ongoing prescription: a lower cash price today can come at the cost of progress toward the protection a Medicare drug plan is built to eventually provide.
What TrumpRx Actually Does Inside Medicare’s Cost-Comparison System
Medicare directs beneficiaries who want to check a drug’s price to TrumpRx.gov as one option among the cost-comparison resources it lists on its own site. The tool is built around cash pricing rather than plan enrollment: a shopper can look up what a specific prescription costs outside insurance, then weigh that figure against what a Part D or Medicare Advantage plan already charges for the same drug. Nothing about the comparison changes what the underlying plan bills for that prescription; it only supplies a second number to consider before deciding where to fill it.
CMS spells out both the purpose and the boundaries of that comparison directly on its site. The agency’s guidance describes TrumpRx as a place to find “special offers and the lowest cash price on prescription drugs,” while stating plainly that a shopper “can’t buy drugs directly from TrumpRx.” The site functions strictly as a reference point for checking a price, not as a pharmacy, a mail-order supplier, or a substitute for a Medicare drug plan’s own network and formulary.
Free retirement updates: Miss an enrollment or claim deadline and it may be gone. The free Retirement Shield newsletter keeps readers ahead of the ones that matter. Get the free newsletter.
Why a Lower Cash Price Doesn’t Advance the Deductible or the Cap
The same page draws a sharper line for anyone who actually uses TrumpRx or a comparable discount card instead of a Medicare plan to fill a prescription. CMS states that such cards “aren’t considered creditable coverage,” and that spending run through one that way simply does not count toward a Medicare plan’s deductible or out-of-pocket maximum for the year. That one sentence is the entire policy: money spent through a discount card sits completely outside the accounting system a Medicare drug plan uses to track how much a beneficiary has paid toward the annual threshold.
The consequence compounds for someone managing a costly, ongoing prescription rather than a single fill. Each purchase routed through a discount card instead of the plan resets that transaction to zero for deductible and cap purposes, no matter how much cash actually changed hands. A shopper chasing the lowest sticker price prescription by prescription can end up further from the point where a Medicare plan’s own out-of-pocket protection takes over, even while spending real money on the same drug.
Nothing in CMS’s guidance discourages price comparison itself; the agency built TrumpRx specifically to make cash prices visible to shoppers. The caution is narrower and more mechanical: comparison shopping and plan-tracked spending are two separate systems that don’t interact. A person can use TrumpRx to inform a decision, but only spending processed through the Medicare plan itself contributes toward that plan’s deductible and out-of-pocket maximum for the year.
A Different Medicare Tool Spreads Costs Without Leaving the Plan
CMS offers a separate option built for people who want to manage drug costs without stepping outside a Medicare plan: the Medicare Prescription Payment Plan, which lets an enrollee spread out-of-pocket prescription costs into monthly installments billed by the person’s own Part D or Medicare Advantage plan, rather than paid in full at the pharmacy counter. Because those installment payments flow through the same plan that tracks deductible and cap progress, CMS’s discount-card caution, aimed specifically at cards used instead of a Medicare plan, does not describe this option.
The tradeoff is different, not absent. CMS’s guidance on the Prescription Payment Plan explains that a participant who misses a payment gets a reminder first, and if the bill still isn’t paid by the date listed in that notice, the enrollee is removed from the payment option. The balance is still owed, but CMS specifies the enrollee “won’t pay any interest or fees” even on a late payment, and remains covered under the underlying Medicare drug or health plan regardless of removal from the payment option itself.
Exit from the arrangement isn’t limited to a missed payment either. CMS’s guidance confirms a participant can leave the Prescription Payment Plan at any time by contacting the health or drug plan directly, without waiting for a renewal period or providing a reason. That flexibility sits alongside the missed-payment rule: departure is available voluntarily, or automatically once a bill goes unpaid past the date on the reminder notice.
CMS’s own materials leave the two tools positioned for different problems entirely. TrumpRx exists to surface the lowest cash price on a given drug, a comparison that stands entirely outside plan accounting. The Prescription Payment Plan exists to make an existing plan’s bill easier to absorb across the year, without changing what that spending counts toward. Read together, Medicare’s guidance leaves a single unresolved tradeoff for anyone comparing the two paths: pay less at the counter right now through a discount card, or stay credited toward the deductible and out-of-pocket maximum that a Medicare drug plan is ultimately built to cap.
This article was produced with AI assistance and reviewed by The Money Overview editorial team.
More Financial Reading
